Figure 3
From: EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
FSCN1 promotes TNBC migration and invasion in vitro. (A) Expression levels of FSCN1 in four mammary carcinoma cell lines were analyzed using real-time PCR. FSCN1 expression was normalized to GAPDH. The data are presented as mean ± S.E.M. from 3 independent experiments, each performed in triplicate. (B) Expression levels of FSCN1 in MDA-MB-231, MDA-MB-468 and MCF-7 cell lines transfected with FSCN1 plasmid or vector as a negative control were analyzed using real-time PCR. (C) Expression levels of FSCN1 in MDA-MB-231, MDA-MB-468 cell and MCF-7 lines transfected with FSCN1 small interfering RNA (siRNA) or the control were analyzed using real-time PCR. D-K. FSCN1 modulates substantial migration, invasion, and growth in MDA-MB-468 (D,E,F), MDA-MB-231 (G, H, I) and MCF-7 (J, K) cell lines. Cells were grown and transiently transfected with FSCN1 plasmid or vector as a negative control for 2 days and subjected to Transwell (D,G,J) and MTT (F,I) assays. Cells were grown and transiently transfected with FSCN1 small interfering RNA (siRNA) or the control for 2 days and subjected to Transwell assays (E,H,K). Values are technical triplicates (were performed independently three times) and represent mean ± S.E.M. *P < 0.01.
